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A majority of Brazilian patients with
rheumatoid arthritis HLA-DRB1 alleles carry
both the HLA-DRB1 shared epitope and
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The objective of the present study was to evaluate the contribution of the shared epitope (SE), the rheumatoid arthritis (RA)
protection model, and the occurrence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in RA patients from a genetically
diverse population. One hundred and forty Brazilian RA patients and 161 matched controls were typed for HLA-DRB1 alleles
using amplified DNA hybridized with sequence-specific oligonucleotide probes or primers. Patients were stratified according to
the presence or absence of SE (DRB1*0401, *0404, *0405, *0101, *1001, and *1402), of the DERAA alleles (DRB1*0103, *0402,
*1102, *1103, *1301, *1302, and *1304), and X (all other alleles). Anti-CCP antibodies were measured by ELISA. The combined
frequency of SE-positive alleles was significantly greater (76.4 vs 23.6%, P < 0.0001) than the controls. The SE/SE and SE/X
genotypes were over-represented (P < 0.0001, OR = 6.02) and DERAA/X was under-represented in RA patients (P < 0.001, OR
= 0.49), whereas the frequencies of the SE/DERAA, X/X and X/DERAA genotypes were not significantly different from controls.
The frequency of anti-CCP antibodies was higher in SE-positive patients than in SE-negative patients (64.6 vs 44.7%, P = 0.03;
OR = 2.25). Although the Brazilian population is highly miscegenated, the results of this study support the findings observed in
most genetically homogeneous populations with RA; however, they are not mutually exclusive but rather complementary. The
participation of DRB1-DERAA alleles in protection against RA was also observed (OR = 0.4; 95%CI = 0.23-0.68).
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Introduction
Several lines of evidence indicate the role of major
histocompatibility complex class II molecules in the sus-
ceptibility to seropositive rheumatoid arthritis (RA), par-
ticularly the molecules encoded by HLA-DRB1 genes (1).
DRB1 genes that confer susceptibility to RA include
DRB1*0401 and *0404 alleles among Caucasians (2,3),
DRB1*0405 in East Asian patients (4), DRB1*0101 in
Asian Indians (5) and Ashkenazi Jews (6), DRB1*1001 in
Spaniards (7) and Blacks from South Africa (8), and
DRB1*1402 in native North Americans (9). These RA-
associated alleles share a nucleotide sequence encoding
amino acid residues from position 67 to 74 of the third
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hypervariable region (HV3) of the DRß1 chain, a sequence
that has been named the RA shared epitope (SE) (10,11).
The QRRAA sequence is found in molecules encoded
by DRB1*0404, *0405, *0101, *1001, and *1402 alleles
(sharing arginine at codon 71), and the QKRAA motif is
observed in the DRB1*0401 allele (lysine at codon 71)
(11).
In addition to the association of RA and SE-positive
(SE+) alleles, SE-negative (SE-) alleles are also reported
to influence susceptibility to RA by means of particular
polymorphic anchor residue sequences present in one of
the 5 peptide-binding pockets of the DRß1 chain, i.e.,
pockets 1, 4, 6, 7, and 9 (P1, P4, P6, P7, and P9). These
pockets may influence the peptide-binding specificity of
human leukocyte antigen (HLA) class II molecules, par-
ticularly P4 (12). The SE-associated alleles contribute only
3 residues (70, 71, and 74) to form P4, whereas the fourth
residue is encoded in the first hypervariable region by
codon 13. Alleles which have a neutral or negative electric
charge in their P4, including DRB1*0103, *0402, *07, *08,
*11 (except *1107), *12, and *13, are reported to protect
against the development of RA. In contrast, alleles that
possess a positive electric charge in their P4, such as
DRB1*03, *0403, *0406, *0407, *0901, *1107, *14, *15,
and *16 alleles, have no influence on predisposition to RA
(12,13).
According to the RA protection (RAP) model, a short
amino acid sequence, 70DERAA74, encoded by the HV3 of
the DRB1*0103, *0402, *1102, *1103, *1301, 1302, and
*1304 alleles confers protection against the development
of RA. This model has been supported by several cross-
sectional studies among Caucasian RA patients (14-16).
Autoantibodies to cyclic citrullinated peptides (anti-
CCP antibodies) are highly specific for RA, can be de-
tected years before the first clinical manifestation of RA
(17), and are reported to be a good predictor of the devel-
opment of RA (18). Because the contribution of the SE-
containing HLA alleles to the pathogenesis of RA is not
well understood, the novel information on the association
of SE alleles with anti-CCP–positive disease (17) led us to
evaluate the hypothesis that the SE alleles are a risk factor
for anti-CCP antibodies.
Since the Brazilian population is genetically diverse,
presenting a distinctive pattern of DR alleles and haplo-
types, the evaluation of RA susceptibility models in this
highly miscegenated population can contribute to the un-
derstanding of such associations. In the present study, we
evaluated the contribution of DRB1 alleles stratified ac-
cording to the clustering of SE+ and SE- alleles, the RAP
model alleles and the presence of anti-CCP antibodies
among Brazilian patients with RA.
Subjects and Methods
Patients and controls
A total of 140 (109 women) patients aged 24-79 years
(median = 51), including 98 Whites, self-described to be of
Western and Southern European ancestry, 24 Mulattoes
(Caucasian and Black admixtures), and 18 Blacks, histori-
cally of mostly Bantu, Benin and Senegal African ancestry
(19) presenting RA were evaluated at the University Hos-
pital of the Faculty of Medicine of Ribeirão Preto, Ribeirão
Preto, SP, Brazil, and at the University Hospital of the
Faculty of Medical Sciences of Campinas, Campinas, SP,
Brazil. All patients were typed for HLA-DRB1 alleles and
fulfilled the 1987 revised criteria of the American College of
Rheumatology for the diagnosis of RA (20). As controls,
we evaluated 161 randomly selected normal blood donors
of similar ethnic background from the same geographical
region (21), including 86 Whites, self-described to be of
Western and Southern European ancestry, 47 Blacks (Black
ancestry up to the third generation), historically of mostly
Bantu, Benin and Senegal African ancestry, as reviewed
by Figueiredo et al. (19), and 28 Mulatto (Caucasian and
Black admixtures) individuals. The population assignments
were made by the same investigator who asked the donors
about their ancestry. All individuals were submitted to a
medical examination that showed no evidence of previous
underlying diseases, and presented negative serology for
Chagas’ disease, B- and C-hepatitis, and HIV infection.
The study protocol was approved by the Ethics Committee
of the Faculty of Medicine of Ribeirão Preto, University of
São Paulo, and all subjects gave written informed consent
to participate in the study.
Autoantibody detection
The detection of anti-CCP2 IgG antibodies was per-
formed using commercially available ELISA kits contain-
ing synthetic peptides (Quanta Lite anti-CCP2 Inova, San
Diego, USA). ELISA was performed according to manufac-
turer instructions. Serum samples presenting results >20
U/mL were considered to be positive for the anti-CCP
antibody. Rheumatoid factor was evaluated in all patients
by nephelometry.
HLA-DRB1 typing
HLA-DRB1 alleles were characterized using polymer-
ase chain reaction-amplified DNA hybridized to sequence-
specific oligonucleotide probes, as previously described
(22-24).
Allele clustering according to the SE and the RAP models
The frequency of DRB1 alleles considered to pertain to
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the SE was as the sum of the individual frequency of the
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001
and *1402 alleles. Patients carrying one or two alleles of
shared epitope were classified as SE-positive.
Protective DRB1 alleles (all carrying the HV3 motif
DERAA) are the *0103, *0402, *1102, *1103, *1301 and
*1302 alleles, which have been reported to be
DERAA-positive alleles (12,13). For clarity,
this study uses the term DERAA-encoding
alleles but does not differentiate between the
direct effect of these alleles and the effect of
other alleles in linkage with the DERAA-en-
coding alleles. For analysis, 6 groups were
formed according to the presence of DRB1
alleles, as follows: group A, homozygosity for
the SE (SE/SE); group B, 1 SE allele and 1 no
SE and no DERAA (SE/X); group C, 1 SE and
1 DERAA allele (SE/DERAA); group D, no SE
and no DERAA (X/X); group E, 1 DERAA
allele (X/DERAA), and group F, homozygosity
for DERAA alleles (DERAA/DERAA) (see
Table 2).
Statistical analysis
HLA frequencies observed in patients and
controls were compared using the two-tailed
Fisher exact test with the approximation of
Woolf. Differences were considered to be sig-
nificant at P < 0.05. The odds ratio (OR) was
used to estimate the strength of the associa-
tions. The detection of the strongest associa-
tion between alleles was performed by the
method of Svejgaard and Ryder (25). The
variables (gender, race, age) observed in pa-
tients and controls were compared using un-
paired t-test. Differences were considered to
be significant at P < 0.05.
Results
Frequencies of DRB1 and DRB1 alleles
clustered as SE and DERAA alleles
The individual comparison of the frequency
of the HLA alleles associated with RA, i.e., the
HLA-DRB1*0401, *0404 (*0408), *0405, *0101,
and *1001 alleles, observed in this series was
significantly different from the respective fre-
quency observed in controls (Table 1). Never-
theless, when the frequency of the SE alleles
was considered, it was observed in 39.6% of
RA patients and in only 12.5% of the controls
Table 1. DRB1 and shared epitope (SE) allele frequencies among patients with
rheumatoid arthritis (RA) and controls.
DRB1 Controls Rheumatoid arthritis OR 95%CI
(N = 312 alleles) (N = 280 alleles)
*0101 14 (4.35%) 34 (12.1%)* 2.94 1.54–5.60
*0102 9 (2.8%) 0 (0%)
*0103 1 (0.3%) 0 (0%)
*1501 29 (10.35%) 21 (10.1%)
*1502 4 (1.25%) 2 (0.7%)
*1601 9 (2.8%) 9 (3.2%)
*1602 4 (1.25%) 4 (1.4%)
*0301 35 (10.85%) 25 (8.9%)
*0302 7 (2.15%) 2 (0.7%)
*0401 6 (1.85%) 21 (7.5%)* 4.25 1.69–10.67
*0402 4 (1.25%) 4 (1.4%)
*0403 3 (0.9%) 2 (0.7%)
*0404 7 (4.3%) 21 (7.5%)* 6.40 2.17–18.90
*0405 4 (1.25%) 13 (4.7%)* 3.84 1.24–11.94
*0406 1 (0.3%) 0 (0%)
*0407 7 (2.15%) 0 (0%)
*0411 7 (2.15%) 2 (0.7%)
*1101 19 (5.8%) 7 (2.5%)* 0.39 0.16–0.95
*1102 9 (2.8%) 5 (1.8%)
*1103 4 (1.25%) 2 (0.7%)
*1104 11 (3.4%) 8 (2.8%)
*1105 2 (0.6%) 0 (0%)
*1201 5 (1.55%) 5 (1.8%)
*1202 1 (0.3%) 0 (0%)
*1301 22 (6.85%) 12 (4.3%)
*1302 21 (6.55%) 12 (4.3%)
*1303 2 (0.6%) 0 (0%)
*1304 1 (0.3%) 1 (0.35%)
*1401 12 (3.7%) 5 (1.8%)
*1402 3 (0.9%) 6 (2.15%)
*07 27 (8.4%) 23 (6.45%)
*0801 5 (1.55%) 5 (1.8%)
*0802 3 (0.9%) 1 (0.35%)
*0804 7 (2.15%) 2 (0.7%)
*0807 5 (1.55%) 0 (0%)
*09 7 (2.15%) 10 (3.55%)
*10 5 (1.55%) 16 (5.7%)* 4.38 1.58–12.15
SE-positive 39 (12.5%) 111 (39.6%)* 6.02 3.95–9.17
DERAA-positive 65 (20.8%) 32 (11.42%)* 0.49 0.31–0.77
Data are reported as number with percent in parentheses unless otherwise
stated. SE-positive alleles: DRB1*0101, *0102, *0401, *0404 (*0408), *0405,
*1001 and *1402 alleles; DERAA-positive alleles: DRB1*0103, *0402, *1102,
*1103, *1301 and *1302 alleles. OR = odds ratio; 95%CI = confidence interval
at 95%. HLA frequencies observed in patients and controls were compared
using the two-tailed Fisher exact test with the approximation of Woolf. Differ-
ences were considered to be significant at P < 0.05.
(Pc < 0.0001; Table 1), with an OR of 6.02. The frequency
of DERAA alleles in RA patients was decreased when
compared with controls (11.42 vs 20.8%, P = 0.003, OR =
0.49), conferring protection against the development of RA
(Table 1).
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DERAA-positive alleles (RAP model), and the influence of
the SE
To study the effect of the presence of the DERAA motif
on susceptibility to RA, patients and controls were divided
into 6 groups according to their HLA-DRB1 genotypes
(Table 2). The overall effect of DERAA on the development
of RA was assessed by comparing the presence of the
DERAA motif (groups C, E, and F) versus its absence
(groups A, B, and D). The presence of DERAA was under-
represented in the RA patients (19.3%) versus controls
(37.2%), conferring an OR of 0.40 (P = 0.0006; 95%CI =
0.23-0.68). The effect of the DERAA on the absence of the
SE alleles was assessed by comparing group E (X/DERAA)
plus group F (DERAA/DERAA) with group D (X/X). DERAA
subjects had a reduced risk of developing RA (OR = 0.7),
although the observed effect was not statistically signifi-
cant (P = 0.6; 95%CI = 0.39-1.59).
Association between SE individuals and presence of
anti-CCP antibodies
Anti-CCP antibody was present in 58% of the patients
and rheumatoid factor was present in 60.7%. All patients
with positive anti-CCP antibody also presented positive
rheumatoid factor. Ninety-three patients carried at least
one dose of shared epitope (Table 3). The frequency of
anti-CCP antibodies was higher in SE-positive patients
(64.5%) when compared with SE-negative patients (44.7%;
P = 0.03, OR = 2.63; see Table 4). The distribution of anti-
CCP antibodies was analyzed according to specific SE–
related alleles; we did not observe a higher frequency of
anti-CCP antibodies in RA patients carrying DRB1*0401,
*0404, and *0101 compared with patients who do not carry
these alleles.
Table 2. DRB1 genotype frequencies according to the presence
of predisposing alleles (SE alleles) and protection alleles in
rheumatoid arthritis (RA) patients and controls.
Group DRB1 genotype RA (N = 140) Controls (N = 161)
A SE/SE 26 (18.6%) 6 (3.7%)
B SE/X 57 (40.7%) 25 (15.5%)
C SE/DERAA 10 (7.1%) 10 (6.2%)
D X/X 30 (21.4%) 70 (43.5%)
E X/DERAA 12 (8.6%) 45 (28.0%)
F DERAA/DERAA 5 (3.6%) 5 (3.1%)
Data are reported as number of individuals with percent within
parentheses. The shared epitope (SE) alleles are *0101, *0102,
*0401, *0404, *0405, *0408, *1001 and *1402. The DERAA
alleles are DRB1*0103, *0402, *1102, *1103, *1301, *1302 and
*1304. X = represents all other DRB1 alleles. Groups were
formed according to the presence of DRB1 alleles, as follows:
group A, homozygosity for the SE (SE/SE); group B, 1 SE allele
and 1 no SE and no DERAA (SE/X); group C, 1 SE and 1
DERAA allele (SE/DERAA); group D, no SE and no DERAA (X/
X); group E, 1 DERAA allele (X/DERAA), and group F, homozy-
gosity for DERAA alleles (DERAA/DERAA).
Table 3. Demographic data and laboratory features of the Brazil-
ian rheumatoid arthritis patients in the present study (N = 140).
Variables RA (N = 140) Controls (N = 161)
Gender
Female 109 (77.8%) 120 (74.5%)
Male  31 (22.2%) 41 (25.5%)
Race
White 98 (70%) 86 (53.4%)
Mulatto 24 (17.1%) 28 (17.4%)
Black 18 (12.9%) 47 (29.2%)
Age (years, mean ± SD) 50.41 ± 11.28* 35.5 ± 8.4
median 50 34
minimum-maximum 24-78 22-45
Age at onset of disease 38.5 ± 11.2 NA
(years, mean ± SD)
minimum-maximum 17-57




Anti-CCP-positive 81 (58%) ND
RF-positive 85 (60.7%) ND
SE-positive 93 (66.4%) 39 (12.5%)
Data are reported as number of individuals with percent in paren-
theses unless otherwise stated. RA = rheumatoid arthritis; Anti-
CCP = anti-cyclic citrullinated peptide antibodies; RF = rheuma-
toid factor; SE = shared epitope; NA = not applicable; ND = not
determined. The variables (gender, race, age) observed in pa-
tients and controls were compared using unpaired t-test. Differ-
ences were considered to be significant at P < 0.05. SE-positive
observed in patients and controls were compared using the two-
tailed Fisher exact test with the approximation of Woolf. Differ-
ences were considered to be significant at P < 0.05 (*P <
0.0001).
Table 4. Association of HLA-DRB1 shared epitope (SE) alleles
and anti-cyclic citrullinated peptide (anti-CCP) antibodies in rheu-
matoid arthritis (N = 140).
SE status Anti-CCP- Anti-CCP- OR P
positive negative (95%CI)
SE-positive 60 (64.5%) 33 (35.5%) 2.25 (1.1-4.6) 0.03
SE-negative 21 (44.7%) 26 (55.3%)
Data are reported as number of individuals with percent in paren-
theses unless otherwise stated. Presence or not of anti-CCP
antibodies in SE-positive or SE-negative RA patients was com-
pared using the two-tailed Fisher exact test with the approxima-
tion of Woolf. Differences were considered to be significant at P
< 0.05.
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Discussion
The association between RA and HLA-DR4 antigens
was first reported in the 1970s using cellular techniques
(1), and has recently been reexamined at the genomic
DNA level (2,3). The susceptibility to RA has been reported
to vary according to the ethnic background of the patients,
supporting the “shared epitope” hypothesis (10,11). The
extraordinary genetic diversity of HLA alleles and haplo-
types seen in highly miscegenated populations may result
from the aggregation of distinctive alleles from separate
racial and ethnic groups. The gene bank of the modern
Brazilian population represents the contribution of indi-
viduals of varied racial and ethnic groups. Historic immi-
grations from Europe have distributed various Caucasian
populations, mainly Portuguese, Spanish, Italian and Ger-
man, across Brazil. Brazilian Amerindian populations still
exist as semi-isolated tribal groups, but their genes are
also represented in modern urban populations. In a previ-
ous study, we observed that the frequencies of DRB1*15/
16 (*02), *03, *12, *13, and *09 were similar among Whites,
Blacks and Mulattoes. In contrast, the frequencies of
DRB1*01, *04, *07, *08, *11, and *14 varied between the
different groups. In particular, DRB1*01 genes were de-
tected at approximately the same frequency in Whites and
Mulattoes, but were greater in Blacks. DRB1*04 was simi-
lar in Whites and Mulattoes, but less in Blacks. Regarding
the frequency of individual alleles, HLA-DRB1*0101 and
*1001 were significantly greater in Blacks compared with
Whites (Pc = 0.01 and Pc = 0.01, respectively). The poly-
morphism of DRB1*04 alleles seen in Brazilian Whites was
greater than that observed in the Black population (21).
Since the DRB1*04, *01 and *10 allelic frequencies are
different for White and Black individuals, Pina et al. per-
formed a study on RA patients using exclusively Afro-
Brazilian descendants (Pina FP, Conde RC, Louzada-
Júnior P, Donadi EA, Bertolo MB, unpublished data). They
concluded that Afro-Brazilians with RA inherited a few HLA
genes, which are characteristic of RA not only in African
people, but also in Europeans and Asians who originated
the Brazilian population. In Chile, where HLA-DR4 encod-
ing DRB1 alleles do not encode susceptibility to RA (26),
HLA-DR9 was associated with RA (27). In Japan,
DRB1*0901 was associated with RA after exclusion of
alleles *0101 and *0405 (28). In Kuwait, the association of
HLA-DR3 with RA is explained by a high frequency of HLA-
DR3 together with a relatively low frequency of HLA-DR4
alleles (29). In the present study, we did not observe an
association with either DRB1-09 or DRB1-03 alleles. In
fact, all DRB1 SE alleles were observed in Brazilian RA
patients, including the rare DRB1*1402 allele that is com-
monly observed in individuals of Amerindian heritage,
reflecting the high diversity of the population of the present
study (21). Thus, in highly miscegenated populations the
evaluation of SE frequency instead of individual alleles
pertaining to the SE may be more important in terms of
immunogenetic susceptibility to RA.
The events involved in the pathogenesis of RA are still
unclear, but certainly the etiology is multifactorial. The
shared epitope of HLA-DRB1 is the most important genetic
risk factor. Environmental risk factors are less understood.
Smoking is a candidate, associated with increased citrul-
linated cyclic peptide antibodies (30-32). In this study, we
investigated the associations between HLA class II alleles
and RA and the protective effects of the DERAA-encoding
HLA-DRB1 alleles on RA susceptibility. The question of
whether the effect of DERAA is truly protective or is merely
the result of the absence of predisposing SE encoding
HLA-DRB1 alleles is the subject of some controversy. In
the present study, the comparison of subgroups (Table 2)
allowed differentiation of the effects of protection and non-
protection. In addition, in our population, we showed that
DERAA-encoding HLA-DRB1 alleles independently re-
duce the risk of developing RA. These findings agree with
similar results observed in more homogeneous groups
such as Dutch (13) and Swiss (33) populations.
It has been demonstrated that peptides carrying the
DERAA motif are naturally processed by human antigen-
presenting cells, and it has been suggested that the pro-
tective effect of DERAA is mediated by a specific protec-
tive T cell response (34). Although our results show that
the presence of a predisposing haplotype is not required to
observe the protective effect associated with DERAA, it is
possible that the DERAA sequence, particularly the
DRB1*13 alleles, not only protects against RA but is also
associated with a milder outcome in other diseases, such
as reduced progression to active chronic hepatitis C and B
(35). Theses findings are intriguing and indicate the impor-
tance of elucidating the biologic pathways underlying these
associations, because they might unveil new insight into
immune regulation in relation to the HLA system.
What does this tell us about the disease mechanism?
Assuming differential risks for no susceptibility alleles, this
hypothesis is able to explain data in the literature by
referring to mutations in amino acid sequence at positions
67-74 in the HLA-DRB1 molecule. Thus, this version sup-
ports the notion that this sequence is central in conferring
susceptibility to RA and does not indicate a role for another
gene within the HLA complex. The fact that local amino
acid substitutions induce differential risks suggests that
the interaction of this region with presented peptides,
superantigens or invariant chain may be important in the
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pathogenesis of this disease (13,14).
We observed a higher frequency of anti-CCP anti-
bodies in SE-positive patients (64.5%) compared with SE-
negative patients (44.7%). In contrast, we did not observe
a higher frequency of anti-CCP antibodies in RA patients
that carried specific SE-related alleles, such as DRB1*0401,
*0404, and *0101. Huizinga et al. (17) reported that the SE
alleles were only associated with anti-CCP–positive RA
and not with anti-CCP–negative disease, indicating that the
SE alleles are not associated with RA as such, but rather
with a distinct phenotype of the disease. Although no
formal conclusions on causality can be drawn from this
association study, these findings suggest that anti-CCP
antibodies mediate the association between SE alleles
and RA (36). It would be of interest to repeat the present
study by following the development of anti-CCP antibodies
and RA in healthy asymptomatic persons with and without
SE alleles. Nevertheless, the present findings constitute
an important refinement of the long-known association
between HLA and RA by indicating that the SE alleles are
not primarily associated with RA, but rather with anti-CCP
antibody positivity.
Although SE represents the major contribution to RA
susceptibility, other genes acting individually or in concert
with SE may also be involved (37,38). In addition, environ-
mental factors may further induce epigenetic alterations
contributing to RA pathogenesis (39,40).
We have presented several lines of evidence indicat-
ing the involvement of DRB1 alleles in the susceptibility to
RA. The RAP, SE and P4 polymorphism models are all
associated with the HV3 region of the DRB1 gene and are
useful to understand the immunogenetic susceptibility to
RA. The findings of the present study support current RA
models, and also support the idea that these models are
not mutually exclusive but rather complementary as pro-
posed by Zanelli et al. (16). Even though the Brazilian
population is highly miscegenated, overall the present
findings agree with others observed in genetically more
homogeneous populations.
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